 Connection
Patricia Ladd to Sodium-Glucose Transporter 2
This is a "connection" page, showing publications Patricia Ladd has written about Sodium-Glucose Transporter 2.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.340 |
|
|
|
-
Bjornstad P, Choi YJ, Narongkiatikhun P, Karihaloo A, Prasad PV, Li LP, Tommerdahl KL, Sethi M, Ramesh S, Birznieks C, Clarke A, Elia Y, Curtis J, Clarson C, Weissenkampen D, D'Antonio M, Pinzon Cortes JA, Hampson H, Yuan L, van Eeghen SA, Kanter JE, Bornfeldt KE, Vaisar T, Ladd P, Heerspink HJL, de Boer IH, Goodrich JA, Street K, Tuttle KR, Bergmann KR, Smith C, Hodgin JB, Schaub JA, Nair V, Menon R, Naik AS, McCown PJ, AlAkwaa F, Eddy S, Otto E, Kim NH, Nelson RG, Puelles VG, van Raalte DH, Cherney DZI, Pyle L, Mahmud FH, Kretzler M. SGLT2 inhibition modulates metabolic, vascular, and inflammatory molecular markers in the kidney in youth with type 1 diabetes. Sci Transl Med. 2026 Jul 22; 18(859):eaee1005.
Score: 0.243
-
Sen T, Ju W, Nair V, Ladd P, Menon R, Otto EA, Pyle L, Vigers T, Nelson RG, Arnott C, Neal B, Hansen MK, Kretzler M, Bjornstad P, Heerspink HJL. Sodium glucose co-transporter 2 inhibition increases epidermal growth factor expression and improves outcomes in patients with type 2 diabetes. Kidney Int. 2023 10; 104(4):828-839.
Score: 0.049
-
Schaub JA, AlAkwaa FM, McCown PJ, Naik AS, Nair V, Eddy S, Menon R, Otto EA, Demeke D, Hartman J, Fermin D, O'Connor CL, Subramanian L, Bitzer M, Harned R, Ladd P, Pyle L, Pennathur S, Inoki K, Hodgin JB, Brosius FC, Nelson RG, Kretzler M, Bjornstad P. SGLT2 inhibitors mitigate kidney tubular metabolic and mTORC1 perturbations in youth-onset type 2 diabetes. J Clin Invest. 2023 03 01; 133(5).
Score: 0.048
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|